Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...

Smith’s United Conservative Party government doesn’t yet know the amount Albertans, including many seniors over the age of 65 ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...